Curcumin and paclitaxel induce cell death in breast cancer cell lines

  • Authors:
    • Gloria M. Calaf
    • Richard Ponce-Cusi
    • Flavio Carrión
  • View Affiliations

  • Published online on: July 26, 2018     https://doi.org/10.3892/or.2018.6603
  • Pages: 2381-2388
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is one of the major health issues confronting women; however, treatment with conventional chemotherapeutic drugs is limited. Currently, paclitaxel is used as a therapeutic clinical agent to treat breast cancer that exerts antitumor activity in numerous types of cancer cell. Curcumin (diferuloylmethane), a polyphenol derived from turmeric (Curcuma longa), possesses several properties that could enable it to exert an anticancer effect. Previous reports have demonstrated the synergistic effects of several chemotherapeutic drugs in combination with curcumin. Therefore, the aim of the current study was to evaluate cell death induced by curcumin and paclitaxel alone and in combination in human breast cancer cell lines: MCF7, an epithelial and luminal-like adenocarcinoma cell line triple positive for estrogen and progesterone receptor, and MDA-MB-234, a metastatic human breast cancer cell line triple negative for such receptors, as well as MCF-10F as a normal breast cell line. The results indicated that curcumin and paclitaxel induced apoptosis and necrosis, which was demonstrated through multiple methods, including assays of caspase-3/7 activity, Annexin V, poly(ADP-ribose) polymerase-1 activation and protein expression of caspase-3, nuclear factor (NF)-κB transcription factor and proliferating cell nuclear antigen. The results identified that the combination of curcumin and paclitaxel had a decreased effect on apoptosis in the malignant MDA-MB-231 cell line compared with in MCF7 or MCF-10F. It was demonstrated that the combined treatment with curcumin and paclitaxel resulted in a higher level of apoptosis compared with either substance alone in breast cancer cell lines. Therefore, breast cancer treatment may benefit from the use of a combination of drugs in chemotherapy.

References

1 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Jafari SH, Saadatpour Z, Salmaninejad A, Momeni F, Mokhtari M, Nahand JS, Rahmati M, Mirzaei H and Kianmehr M: Breast cancer diagnosis: Imaging techniques and biochemical markers. J Cell Physiol. 233:5200–5213. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Mustacchi G and De Laurentiis M: The role of taxanes in triple-negative breast cancer: Literature review. Drug Des Devel Ther. 9:4303–4318. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Bidkar AP, Sanpui P and Ghosh SS: Efficient induction of apoptosis in cancer cells by paclitaxel-loaded selenium nanoparticles. Nanomedicine (Lond). 12:2641–2651. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Karimi G, Vahabzadeh M, Lari P, Rashedinia M and Moshiri M: ‘Silymarin’, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 14:308–317. 2011.PubMed/NCBI

6 

Razavi-Azarkhiavi K, Iranshahy M, Sahebkar A, Shirani K and Karimi G: The protective role of phenolic compounds against doxorubicin-induced cardiotoxicity: A comprehensive review. Nutr Cancer. 68:892–917. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Stage TB, Bergmann TK and Kroetz DL: Clinical pharmacokinetics of paclitaxel monotherapy: An updated literature review. Clin Pharmacokinet. 57:7–19. 2018. View Article : Google Scholar : PubMed/NCBI

8 

Zheng X, Wang C, Xing Y, Chen S, Meng T, You H, Ojima I and Dong Y: SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells. Int J Oncol. 50:893–902. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Wang Y, Yu J, Cui R, Lin J and Ding X: Curcumin in treating breast cancer: A review. J Lab Autom. 21:723–731. 2016. View Article : Google Scholar : PubMed/NCBI

10 

Robles-Escajeda E, Das U, Ortega NM, Parra K, Francia G, Dimmock JR, Varela-Ramirez A and Aguilera RJ: A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol (Dordr). 39:265–277. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Ko EY and Moon A: Natural products for chemoprevention of breast cancer. J Cancer Prev. 20:223–231. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Księżakowska-Łakoma K, Żyła M and Wilczyński JR: Mitochondrial dysfunction in cancer. Prz Menopauzalny. 13:136–144. 2014.PubMed/NCBI

13 

Cui L, Bu W, Song J, Feng L, Xu T, Liu D, Ding W, Wang J, Li C, Ma B, et al: Apoptosis induction by alantolactone in breast cancer MDA-MB-231 cells through reactive oxygen species-mediated mitochondrion-dependent pathway. Arch Pharm Res. 41:299–313. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Li J, Dou D, Li P, Luo W, Lv W, Zhang C, Song X, Yang Y, Zhang Y, Xu Y, et al: PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population. Tumour Biol. 39:10104283177069142017. View Article : Google Scholar : PubMed/NCBI

15 

Lucarini L, Durante M, Lanzi C, Pini A, Boccalini G, Calosi L, Moroni F, Masini E and Mannaioni G: HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway. J Cell Mol Med. 21:324–335. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Schuhwerk H, Atteya R, Siniuk K and Wang ZQ: PARPing for balance in the homeostasis of poly(ADP-ribosyl)ation. Semin Cell Dev Biol. 63:81–91. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Darvishi B, Farahmand L, Eslami-S Z and Majidzadeh-A K: NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer. Tumour Biol. 39:10104283177069192017. View Article : Google Scholar : PubMed/NCBI

18 

Baskari S, Govatati S, Madhuri V, Nallabelli N; K PM, ; Naik S, Poornachandar Balka S, Tamanam RR and Devi VR: Influence of autocrine growth hormone on NF-κB activation leading to epithelial-mesenchymal transition of mammary carcinoma. Tumour Biol. 39:10104283177191212017. View Article : Google Scholar : PubMed/NCBI

19 

Juríková M, Danihel Ľ, Polák Š and Varga I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 118:544–552. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Wang SC: PCNA: A silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 35:178–186. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Lossi L, Cocito C, Alasia S and Merighi A: Ex vivo imaging of active caspase 3 by a FRET-based molecular probe demonstrates the cellular dynamics and localization of the protease in cerebellar granule cells and its regulation by the apoptosis-inhibiting protein survivin. Mol Neurodegener. 11:342016. View Article : Google Scholar : PubMed/NCBI

22 

Gallardo M and Calaf GM: Curcumin and epithelial-mesenchymal transition in breast cancer cells transformed by low doses of radiation and estrogen. Int J Oncol. 48:2534–2542. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Ponce-Cusi R and Calaf GM: Apoptotic activity of 5-fluorouracil in breast cancer cells transformed by low doses of ionizing α-particle radiation. Int J Oncol. 48:774–782. 2016. View Article : Google Scholar : PubMed/NCBI

24 

Yan G, Graham K and Lanza-Jacoby S: Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog. 52:404–411. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Chen D, Dai F, Chen Z, Wang S, Cheng X, Sheng Q, Lin J and Chen W: Dimethoxy curcumin induces apoptosis by suppressing survivin and inhibits invasion by enhancing E-cadherin in colon cancer cells. Med Sci Monit. 22:3215–3222. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Ganta S and Amiji M: Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 6:928–939. 2009. View Article : Google Scholar : PubMed/NCBI

27 

Quispe-Soto ET and Calaf GM: Effect of curcumin and paclitaxel on breast carcinogenesis. Int J Oncol. 49:2569–2577. 2016. View Article : Google Scholar : PubMed/NCBI

28 

Calaf GM and Hei TK: Establishment of a radiation- and estrogen-induced breast cancer model. Carcinogenesis. 21:769–776. 2000. View Article : Google Scholar : PubMed/NCBI

29 

Calaf GM, Echiburú-Chau C, Wen G, Balajee AS and Roy D: Effect of curcumin on irradiated and estrogen-transformed human breast cell lines. Int J Oncol. 40:436–442. 2012.PubMed/NCBI

30 

Calaf GM, Echiburú-Chau C, Roy D, Chai Y, Wen G and Balajee AS: Protective role of curcumin in oxidative stress of breast cells. Oncol Rep. 26:1029–1035. 2011.PubMed/NCBI

Related Articles

Journal Cover

October 2018
Volume 40 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Calaf, G.M., Ponce-Cusi, R., & Carrión, F. (2018). Curcumin and paclitaxel induce cell death in breast cancer cell lines. Oncology Reports, 40, 2381-2388. https://doi.org/10.3892/or.2018.6603
MLA
Calaf, G. M., Ponce-Cusi, R., Carrión, F."Curcumin and paclitaxel induce cell death in breast cancer cell lines". Oncology Reports 40.4 (2018): 2381-2388.
Chicago
Calaf, G. M., Ponce-Cusi, R., Carrión, F."Curcumin and paclitaxel induce cell death in breast cancer cell lines". Oncology Reports 40, no. 4 (2018): 2381-2388. https://doi.org/10.3892/or.2018.6603